A randomized double-blind controlled study of Guizhi Decoction in the treatment of early rheumatoid arthritis based on ultrasonic evaluatio
- Conditions
- Rheumatoid arthritis
- Registration Number
- ITMCTR2000003615
- Lead Sponsor
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Meet the diagnostic criteria for RA; Meet the diagnostic criteria for active RA.
2. Aged 18-75 years with a course of disease less than 1 year.
3. Disease Activity Score in 28 joints-Erythrocyte Sedimentation Rate (DAS28-ESR) >= 2.6 (rounded to 1 decimal place).
4. Patients receiving NSAIDs and hormone therapy were given a stable dose for at least 30 days before entering the trial, and remained the same for the rest of the treatment.
5. Patients receiving other DMARDs must be interrupted for at least 30 days before entering the trial.
1. Patients with interstitial lung disease; Accompanied by severe elevations of liver enzymes.
2. Women who are pregnant, breast-feeding or who have recently prepared for childbirth.
3. Persons who are allergic or sensitized to the test drugs.
4. Patients with severe primary diseases of the heart, liver, kidneys, brain, endocrine system and hematopoietic system, psychiatric disorders, etc.
5. At the same time with other rheumatic diseases such as systemic lupus erythematosus, Sjogren's syndrome, myositis and so on.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method S7;DAS28;Joint tenderness count;CRP;Evaluation of TCM syndrome curative effect;VAS;routine blood test;ESR;Joint swelling count;
- Secondary Outcome Measures
Name Time Method sCD14;TIMP;MMP3;CD14+;